Integration of genomics, high throughput drug screening, and personalized xenograft models as a novel precision medicine paradigm for high risk pediatric cancer

• Published in: Cancer biology & therapy Vol. 19; no. 12; pp. 1078 - 1087
• Main Authors: Tsoli, Maria, Wadham, Carol, Pinese, Mark, Failes, Tim, Joshi, Swapna, Mould, Emily, Yin, Julia X, Gayevskiy, Velimir, Kumar, Amit, Kaplan, Warren, Ekert, Paul G, Saletta, Federica, Franshaw, Laura, Liu, Jie, Gifford, Andrew, Weber, Martin A, Rodriguez, Michael, Cohn, Richard J, Arndt, Greg, Tyrrell, Vanessa, Haber, Michelle, Trahair, Toby, Marshall, Glenn M, McDonald, Kerrie, Cowley, Mark J, Ziegler, David S
• Format: Journal Article
• Language: English
• Published: United States Taylor & Francis 02.12.2018; Taylor & Francis Group
• Subjects: Age Factors; Animals; Bedside to Bench Report; Biopsy; Child; Disease Models, Animal; DNA Methylation; Drug Screening Assays, Antitumor - methods; Genomics - methods; high throughput drug screening; High-Throughput Screening Assays; Humans; Magnetic Resonance Imaging; Male; Mice; Neoplasms - diagnosis; Neoplasms - drug therapy; Neoplasms - genetics; Neoplasms - mortality; patient derived xenografts; pediatric brain tumors; personalized medicine; Precision Medicine - methods; Recurrence; targeted treatment; Treatment Outcome; Xenograft Model Antitumor Assays; patient derived xenografts; pediatric brain tumors; high throughput drug screening; personalized medicine; targeted treatment

Pediatric high grade gliomas (HGG) are primary brain malignancies that result in significant morbidity and mortality. One of the challenges in their treatment is inter- and intra-tumoral heterogeneity. Precision medicine approaches have the potential to enhance diagnostic, prognostic and/or therapeu...